- Drug Coverage
- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Safety & Recalls
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
AMCP changes name of foundation, appoints new board members
The Academy of Managed Care Pharmacy has changed the foundation’s name to the Academy of Managed Care Pharmacy Foundation. In addition, it has elected four new members to its board of trustees, during the AMCP’s 25th annual meeting and exposition in San Diego.
The Academy of Managed Care Pharmacy has changed the foundation’s name to the Academy of Managed Care Pharmacy Foundation. In addition, it has elected 4 new members to its board of trustees, during the AMCP’s 25th annual meeting and exposition in San Diego.
New members to the AMCP Foundation’s board include: Annette D. Boyer, president of CECity, Inc.; Richard A. Zabinski, vice president, Prime Therapeutics, LLC; Edwin C. Hedblom, treasurer, 3M Medical; and Robert DeLuca, secretary of Archimedes Pharma US, Inc. Two trustees were re-elected to one-year terms: Perry Cohen, The Pharmacy Group, LLC, and Kathleen Kaa, Genentech USA.
“Since its inception in 1990, the AMCP Foundation has played an integral role in supporting the research and education agenda of AMCP. I welcome the newest members to our Board of Trustees and look forward to working with them to advance the professional development of healthcare practitioners in the managed care community,” said Edith A. Rosato, RPh, IOM, CEO of the Academy and Chair of the Foundation’s Board of Trustees.
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Read More
FDA Approves Stelara Biosimilar, Selarsdi
April 18th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Read More
